Opus Genetics is trading at $4.43, down 5.05%, after no clear negative company-specific announcement was identified for September 8, 2026.
- Investors are awaiting September 9 topline OPGx-BEST1 Cohort 1 data, scheduled for an 8:00 a.m. ET webcast.
- H.C. Wainwright reaffirmed a Buy rating and $8.00 price target ahead of the presentation.
- Broader markets are modestly lower, but this does not establish a direct cause.